GILEAD SCIENCES, INC. GILD
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances)
Chart by TradingView
7/9
Piotroski F — financial health
3.28
Altman Z″ — distress risk · safe
47.0%
Dividend payout · moderate
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $29.4B | $8.5B | — | $9.5B | $22.6B |
| 2024 | $28.8B | $480.0M | — | $10.3B | $19.2B |
| 2023 | $27.1B | $5.7B | — | $7.4B | $22.7B |
| 2022 | $27.3B | $4.6B | — | $8.3B | $21.2B |
| 2021 | $27.3B | $6.2B | — | $10.8B | $21.1B |
| 2020 | $24.7B | $123.0M | — | $7.5B | $18.2B |
Why these scores methodology →
Piotroski F-score: 7/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 3.28 (safe)
- Working capital / assets 0.111
- Retained earnings / assets 0.233
- EBIT / assets 0.17
- Equity / liabilities 0.621
Source: SEC EDGAR filings · CIK 0000882095 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.